Metabolic Abnormalities Related to Treatment with Selective Serotonin Reuptake Inhibitors in Patients with Schizophrenia or Bipolar Disorder

Journal of Clinical Psychopharmacology

Volumn 36, Issue 6, 2016, Pages 615-620

  Fjukstad, Katrine Kveli ^a,b   Engum, Anne ^c   Lydersen, Stian ^d   Dieset, Ingrid ^e   Steen, Nils Eiel ^e,f   Andreassen, Ole A ^e   Spigset, Olav ^b,c  

^a Levanger Hospital   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^c TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^d Regional Centre for Child and Youth Mental Health and Child Welfare   (Norway)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f VESTRE VIKEN HOSPITAL TRUST   (Norway)

Author keywords

antidepressants; antipsychotics; bipolar disorder; metabolic abnormalities; schizophrenia; selective serotonin reuptake inhibitors

Indexed keywords

CITALOPRAM; ESCITALOPRAM; FLUOXETINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NORFLUOXETINE; PAROXETINE; SERTRALINE; TRIACYLGLYCEROL; CHOLESTEROL; GLUCOSE BLOOD LEVEL; HIGH DENSITY LIPOPROTEIN; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGE; ARTICLE; BIPOLAR DISORDER; BODY MASS; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; COMBINATION DRUG THERAPY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; METABOLIC DISORDER; METABOLIC SYNDROME X; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; REFERENCE VALUE; SCHIZOPHRENIA; SEX; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; BLOOD; BLOOD PRESSURE; METABOLISM; PHYSIOLOGY;

ADULT; BIPOLAR DISORDER; BLOOD GLUCOSE; BLOOD PRESSURE; CHOLESTEROL; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LIPOPROTEINS, HDL; MALE; SCHIZOPHRENIA; SEROTONIN UPTAKE INHIBITORS; TRIGLYCERIDES; WAIST CIRCUMFERENCE;

EID: 84991478632     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000582     Document Type: Article

References (37)

1. Tiihonen J, Lönnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009;374:620-627.
2. Nordentoft M, Wahlbeck K, Hällgren J, et al. Excess mortality, causes of death and life expectancy in 270,770 patients with recent onset of mental disorders in Denmark, Finland and Sweden. PLoS One. 2013;8:e55176.
3. Smith DJ, Martin D, McLean G, et al. Multimorbidity in bipolar disorder and undertreatment of cardiovascular disease: a cross sectional study. BMC Med. 2013;11:263.
4. Weiner M, Warren L, Fiedorowicz JG. Cardiovascular morbidity and mortality in bipolar disorder. Ann Clin Psychiatry. 2011;23:40-47.
5. Ringen PA, Engh JA, Birkenæs AB, et al. Increased mortality in schizophrenia due to cardiovascular disease-a non-systematic reviewof epidemiology, possible causes, and interventions. Front Psychiatry. 2014; 5:137.
6. Laursen TM, Munk-Olsen T, Agerbo E, et al. Somatic hospital contacts, invasive cardiac procedures, and mortality from heart disease in patients with severe mental disorder. Arch Gen Psychiatry. 2009;66:713-720.
7. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80:19-32.
8. McElroy SL, Keck PE Jr.Metabolic syndrome in bipolar disorder: a review with a focus on bipolar depression. J Clin Psychiatry. 2014;75:46-61.
9. Birkenæs AB, Opjordsmoen S, Brunborg C, et al. The level of cardiovascular risk factors in bipolar disorder equals that of schizophrenia: a comparative study. J Clin Psychiatry. 2007;68:917-923.
10. Heiskanen T, Niskanen L, Lyytikainen R, et al. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry. 2003;64:575-579.
11. Taylor V, McKinnon MC, Macdonald K, et al. Adults with mood disorders have an increased risk profile for cardiovascular disease within the first 2 years of treatment. Can J Psychiatry. 2010;55:362-368.
12. Andreassen OA, Djurovic S, Thompson WK, et al. Improved detection of common variants associated with schizophrenia by leveraging pleiotropy with cardiovascular-disease risk factors. Am J Hum Genet. 2013;92: 197-209.
13. Hasnain M, Fredrickson SK, Vieweg WV, et al. Metabolic syndrome associated with schizophrenia and atypical antipsychotics. Curr Diab Rep. 2010;10:209-216.
14. Hasnain M, Vieweg WV. Weight considerations in psychotropic drug prescribing and switching. Postgrad Med. 2013;125:117-129.
15. Hasnain M, Vieweg WV, Hollett B.Weight gain and glucose dysregulation with second-generation antipsychotics and antidepressants: a review for primary care physicians. Postgrad Med. 2012;124:154-167.
16. Sepehry AA, Potvin S, Elie R, et al. Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta-analysis. J Clin Psychiatry. 2007;68:604-610.
17. Baldessarini RJ, Leahy L, Arcona S, et al. Patterns of psychotropic drug prescription for U.S. patients with diagnoses of bipolar disorders. Psychiatr Serv. 2007;58:85-91.
18. Vancampfort D, Correll CU, Wampers M, et al. Metabolic syndrome and metabolic abnormalities in patients with major depressive disorder: a meta-analysis of prevalences andmoderating variables. Psychol Med. 2014; 44:2017-2028.
19. Bailey DL, Le Mellédo JM. Effects of selective serotonin reuptake inhibitors on cholesterol levels in patients with panic disorder. J Clin Psychopharmacol. 2003;23:317-319.
20. Kim EJ, Yu BH. Increased cholesterol levels after paroxetine treatment in patients with panic disorder. J Clin Psychopharmacol. 2005;25: 597-599.
21. Herrán A, Ramírez ML, Carrera M, et al. Panic disorder, treatment with selective serotonin reuptake inhibitors, and cholesterol levels. J Clin Psychopharmacol. 2006;26:538-540.
22. Lara N, Baker GB, Archer SL, et al. Increased cholesterol levels during paroxetine administration in healthy men. J Clin Psychiatry. 2003;64: 1455-1459.
23. Wei F, Crain AL, Whitebird RR, et al. Effects of paroxetine and sertraline on low-density lipoprotein cholesterol: an observational cohort study. CNS Drugs. 2009;23:857-865.
24. Le Melledo JM, Mailo K, Lara N, et al. Paroxetine-induced increase in LDL cholesterol levels. J Psychopharmacol. 2009;23:826-830.
25. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112: 2735-2752.
26. Ræder MB, Bjelland I, Emil Vollset S, et al. Obesity, dyslipidemia, and diabetes with selective serotonin reuptake inhibitors: the Hordaland Health Study. J Clin Psychiatry. 2006;67:1974-1982.
27. Beyazyuz M, Albayrak Y, Egilmez OB, et al. Relationship between SSRIs and metabolic syndrome abnormalities in patients with generalized anxiety disorder: a prospective study. Psychiatry Investig. 2013;10:148-154.
28. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD index 2016. Available at http://www.whocc.no/atc-ddd-index/. Accessed April 4, 2016.
29. Reis M, Aamo T, Spigset O, et al. Serum concentrations of antidepressant drugs in a naturalistic setting: compilation based on a large therapeutic drug monitoring database. Ther Drug Monit. 2009;31:42-56.
30. Hiemke C, Baumann P, Bergemann N, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry. 2011;44:195-235.
31. de Jonghe F, Ravelli DP, Tuynman-Qua H. A randomized, double-blind study of fluoxetine and maprotiline in the treatment of major depression. Pharmacopsychiatry. 1991;24:62-67.
32. Michelson D, Amsterdam JD, Quitkin FM, et al. Changes in weight during a 1-year trial of fluoxetine. Am J Psychiatry. 1999;156:1170-1176.
33. Fava M, Judge R, Hoog SL, et al. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. J Clin Psychiatry. 2000;61:863-867.
34. Shay CM, Gooding HS, Murillo R, et al. Understanding and improving cardiovascular health: an update on the American Heart Association's concept of cardiovascular health. Prog Cardiovasc Dis. 2015;58: 41-49.
35. van Buuren S. Flexible Imputation of Missing Data. BocaRaton, FL: CRC Press; 2012.
36. Rodwell L, Lee KJ, Romaniuk H, et al. Comparison of methods for imputing limited-range variables: a simulation study. BMC Med Res Methodol. 2014;14:57.
37. Spina E, de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol. 2007;100:4-22.